Generic Name: cabotegravir + rilpivirine
Drug Class: Complete Regimens
Company: ViiV Healthcare and Janssen Therapeutics
Approval Status: Approved
Generic Version Available: No
Cabenuva (cabotegravir + rilpivirine) is a long-acting injectable regimen approved as a treatment for HIV. It has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
Cabenuva is a long-acting injectable HIV regimen. It contains two different types of HIV drugs: the experimental integrase inhibitor cabotegravir and an injectable version of rilpivirine (sold in pill form as Edurant).
It was approved as maintenance therapy for adults living with HIV who have achieved viral suppression (a viral load less than 50) on daily oral treatment and who have no history treatment failure and no known or suspected viral resistance to either cabotegravir or rilpivirine. Cabenuva was approved in January 2021.
This is a long-acting injectable regimen administered every four weeks. People who switch from their current regimen should take cabotegravir pills, known as Vocabria, plus Edurant for a month to ensure that the combination is well tolerated. After that, they will receive two injections in the buttocks administered by a health care provider once a month. Vocabria and Edurant pills can also be used as a short-term regimen if someone has to miss a planned Cabenuva injection appointment.
The most common side effect is injection site reactions such as pain, redness or swelling. Other adverse events, including fever, fatigue, headache, and muscle pain, nausea, sleep disorders, dizziness and rash, are less common.
Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/
Last Reviewed: January 21, 2021